BioStem Technologies (OTCMKTS:BSEM) Trading Down 0.6% - Time to Sell?

Key Points

• BioStem Technologies (OTCMKTS:BSEM) saw a 0.6% decrease in trading, closing at $4.80 with 32,700 shares exchanged, which is a 55% drop from its average daily volume.
• The company has a market capitalization of $80.49 million, a PE ratio of 4.21, and its stock has struggled, reflected by a significant decline from an average price of $6.82 over the past 50 days.
• BioStem Technologies focuses on developing and producing pharmaceutical and regenerative medicine products, targeting conditions like joint pain and autoimmune diseases through stem cell therapies.

BioStem Technologies, Inc. (OTCMKTS:BSEM - ) dropped 0.6% during trading on Wednesday . The company traded as low as $4.77 and last traded at $4.80. Approximately 32,700 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 72,406 shares. The stock had previously closed at $4.83.

BioStem Technologies Price Performance

The stock has a market capitalization of $80.49 million, a PE ratio of 4.21 and a beta of -0.44. The business has a 50 day moving average price of $6.82 and a 200 day moving average price of $10.18.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.